Harrow (NASDAQ:HROW – Get Free Report) will likely be announcing its earnings results after the market closes on Monday, March 17th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $58.41 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Harrow Stock Performance
Shares of NASDAQ HROW opened at $23.01 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The firm’s 50-day moving average price is $30.45 and its two-hundred day moving average price is $38.85. Harrow has a 52-week low of $9.30 and a 52-week high of $59.23. The stock has a market capitalization of $819.50 million, a P/E ratio of -24.48 and a beta of 0.69.
Wall Street Analyst Weigh In
Several brokerages have commented on HROW. HC Wainwright began coverage on shares of Harrow in a research note on Thursday, February 6th. They issued a “buy” rating and a $57.00 price target on the stock. B. Riley lowered their price objective on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.
Harrow Company Profile
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Featured Stories
- Five stocks we like better than Harrow
- How to trade using analyst ratings
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What is a penny stock? A comprehensive guide
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Stock Market Sectors: What Are They and How Many Are There?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.